Cubist Pharmaceuticals to Acquire Trius Therapeutics For $13.50 Per Share
July 30, 2013 at 16:45 PM EDT
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST ) and Trius Therapeutics, Inc. (NASDAQ: TSRX ) today announced that they have signed a definitive agreement under which Cubist will acquire all outstanding shares of Trius for $13.50 per share in cash or approximately $707 million on a fully diluted basis. In
